Recent developments include licensing of liver disease diagnostic assets, leadership changes, capital raises, and partnerships to commercialize diagnostic tests.

• In February 2026, Hepion licensed liver disease diagnostic assets from Cirna Diagnostics, including a novel biomarker assay for early diagnosis of hepatocellular carcinoma, with upfront and milestone payments plus royalties [S2].
• In April 2026, the company completed a private placement offering, issuing 17.5 million shares at $0.04 per share, raising $700,000 in gross proceeds [S2].
• In June 2025, Hepion appointed Kaouthar Lbiati as Interim CEO [N13].
• The company transitioned from Nasdaq to OTC Markets following a delisting notice in 2025 [N14].
• Hepion entered a binding letter of intent with New Day Diagnostics to in-license CE-marked diagnostic tests for commercialization [N15].

Hepion Pharmaceuticals has advanced its clinical pipeline with a Phase 2 trial meeting efficacy and safety endpoints for its lead therapeutic candidate. The in-licensing of novel diagnostic assays and partnerships for commercialization could expand its product offerings. The company maintains strong liquidity to support ongoing development activities. Leadership appointments and capital raises indicate active management and resource mobilization to execute its strategy.

Hepion Pharmaceuticals faces risks typical of clinical-stage biopharmaceutical companies, including clinical trial uncertainties, regulatory hurdles, and the need for additional capital. The transition from Nasdaq to OTC Markets may impact investor perception and liquidity. The company reported a net loss in Q1 2026 and has yet to generate revenue, reflecting ongoing operational risks. Dependence on partnerships and licensing agreements introduces execution risks.

Hepion Pharmaceuticals' moat is based on its proprietary liver disease diagnostic assets and therapeutic candidates in clinical development. The in-licensing of novel biomarker assays for early detection of hepatocellular carcinoma provides a potential competitive advantage in a specialized niche. The company's intellectual property agreements and partnerships for commercialization support its position in the liver disease diagnostics and therapeutics market. However, as a clinical-stage company, its moat is contingent on successful clinical and regulatory progress.

• Clinical and Regulatory Risk: The company’s therapeutic and diagnostic candidates are in clinical development and subject to regulatory approval processes that may delay or prevent commercialization.
• Financial Risk: Hepion reported a net loss and relies on capital raises and partnerships to fund operations, which may dilute shareholders or limit operational flexibility.
• Market and Listing Risk: The transition from Nasdaq to OTC Markets may reduce visibility and liquidity for investors, potentially impacting capital access.
• Execution Risk: Successful commercialization depends on effective partnerships and management execution, with risks related to licensing agreements and market adoption.

• Hepion Pharmaceuticals, Inc. is a Delaware corporation headquartered in New Jersey, United States.
• The company is engaged in pharmaceutical development, focusing on liver disease diagnostics and therapeutics.
• Hepion licensed liver disease diagnostic assets from Cirna Diagnostics, LLC in February 2026, including a novel biomarker assay for early diagnosis of hepatocellular carcinoma, with upfront and milestone payments plus royalties [S2].
• The company completed a private placement offering in April 2026, issuing 17.5 million shares of common stock at $0.04 per share, raising gross proceeds of $700,000 [S2].
• Hepion Pharmaceuticals transitioned from Nasdaq to OTC Markets following a delisting notice in 2025 [N14].
• The company appointed Kaouthar Lbiati as Interim CEO in June 2025 [N13].
• Financial snapshot as of March 31, 2026, shows cash and equivalents of $13.9 million, current assets of $2.7 million, current liabilities of $0.7 million, a current ratio of 3.68, and a cash ratio of 18.93, indicating strong liquidity [S2].
• The company reported a net loss of $810,791 and basic and diluted EPS of -$0.07 for Q1 2026 [S2].
• There have been no material changes in risk factors since the 2025 Form 10-K [S2].
• The company has entered into employment agreements with key executives in May 2026 [S2].
• Hepion has engaged in partnerships to commercialize diagnostic tests, including a binding LOI with New Day Diagnostics for in-licensing CE-marked diagnostic tests [N15].